Clinical Trial: A key to Industry Innovation and Healthy Taiwan Vision
Over the past few years, global instability and rapid advances in AI, digitisation, and biomedical technologies have reshaped industries worldwide. While Taiwan’s strength has long been in technology, its advantages extend to top-tier biomedical talent and research capacity, a high-quality healthcare system, world-class biobank, and proven resilience during the COVID-19 pandemic. Combining these with AI, big data, and 5G, Taiwan is uniquely positioned to develop decentralised clinical trials (DCT), real-world evidence (RWE), smart wards, and remote monitoring, securing a key role in the global biomedical landscape.
By focusing on speed, quality, transparency, and predictability in clinical trials, Taiwan can attract leading global pharma companies to conduct research locally. Benefits include earlier patient access to innovative therapies, improved treatment quality and affordability, and support for Health Technology Assessment through robust local data. Moreover, trials foster talent development and technological upgrades, raising healthcare standards and clinical research culture.
In order to create a competitive clinical trial ecosystem, a One-Stop Platform is proposed. This platform will integrate resources and streamline processes, covering project sourcing, patient recruitment, and drug import/export, along with contract standardisation and electronic signatures, and eventually align policies with "Healthy Taiwan" objectives.
A Healthy and Sustainable Taiwan: Building a Globally Competitive Clinical-Trial Ecosystem
